Skip to main content

Table 1 Comparison of epidemiological, clinical characteristics and outcome of patients with BSIs due to Candida parapsilosis and Candida albicans

From: Factors related to outcome of bloodstream infections due to Candida parapsilosis complex

Variables Patients with BSIs due to:
C. parapsilosis (n = 63) C. albicans (n = 146) P valuea
Age (years), median (IQR)b 67 (43–76) 51 (66–77) 0.133
Neonates (<3 months) 1 (2) 5 (3) 0.465
Elderly (>65 years) 32 (51) 72 (49) 0.844
Male sex, n (%) 35 (56) 91 (63) 0.358
Ward
 Internal Medicine, n (%) 25 (40) 52 (36) 0.448
 Surgery, n (%) 17 (27) 32 (22)  
 Intensive Care Unit, n (%) 21 (33) 62 (43)  
Comorbidities, n (%) 57 (90) 137 (94) 0.387
 Chronic pulmonary diseases, n (%)c 9 (14) 11 (8) 0.127
 Haematological malignancy, n (%) 1 (2) 8 (5) 0.203
 Cardiovascular diseases, n (%)d 27 (43) 67 (46) 0.685
 Neurological diseases, n (%)e 10 (16) 24 (16) 0.919
 Gastrointestinal diseases, n (%)f 21 (33) 43 (29) 0.576
 Diabetes mellitus, n (%) 8 (13) 28 (19) 0.254
 Solid tumors, n (%) 15 (24) 43 (30) 0.403
 Chronic renal failure, n (%) 7 (11) 12 (8) 0.504
Previous surgery (<30 days), n (%) 32 (51) 67 (46) 0.514
 Gastrointestinal surgery, n (%) 8 (13) 19 (13) 0.950
 Cardiovascular surgery, n (%) 13 (21) 28 (19) 0.807
 Other surgery, n (%) g 12 (19) 24 (16) 0.646
Central venous catheter, n (%) 56 (89) 127 (87) 0.702
 BSI CVC-related, n (%) 36 (64) 57 (45) 0.015
Other devices, n (%)h 57 (90) 129 (88) 0.653
Previous invasive procedures (<72 h), n (%)i 16 (25) 44 (30) 0.486
Parenteral nutrition, n (%) 43 (68) 105 (72) 0.592
Immunosuppressive therapy, n (%)j 18 (29) 56 (34) 0.174
Neutropenia, n (%) 4 (6) 7 (5) 0.644
Septic shock, n (%) 2 (3) 12 (8) 0.180
Prior antibiotic therapy, n (%) 58 (92) 139 (95) 0.370
Previous antifungal therapy (<30 days), n (%) 5 (8) 21 (14) 0.195
Concomitant bacteriemia, n (%) 15 (24) 40 (27) 0.588
Other coinfections, n (%)k 39 (62) 89 (61) 0.897
Appropriate antifungal therapy, n (%)l 38 (60) 92 (63) 0.712
 Primary azole therapy 41 (65) 77 (53) 0.098
 Primary echinocandin therapy 7 (11) 34 (23) 0.041
 Primary polyene therapy 1 (2) 3 (2) 0.820
 None 14 (22) 32 (22) 0.961
Overall mortality, n (%) 17 (27) 61 (42) 0.042
 Early mortality (days 1–7), n (%) 4 (6) 24 (17) 0.049
 Late mortality (days 8–30), n (%) 13 (21) 37 (25) 0.464
  1. aComparisons between groups were performed using Wilcoxon rank sum test for quantitative variables and Chi-Square test (or Fisher Exact Test when expected frequencies were less than five) for qualitative variables
  2. bIQR, Interquartile range
  3. cChronic pulmonary diseases include asthma, chronic bronchitis, emphysema and lung fibrosis
  4. dCardiovascular diseases include heart failure, ischemic heart disease, endocarditis and arrhythmia
  5. eNeurological diseases include Parkinson’s disease, Alzheimer’s disease and paralysis
  6. fGastrointestinal diseases include Crohn’s disease, ulcerative colitis, chronic pancreatitis and gallbladder stones
  7. g Other surgery includes plastic surgery, thoracic surgery, orthopaedic surgery, urological surgery and neurosurgery
  8. h Other devices include urinary catheter, surgical drainage, cutaneous gastrostomy and tracheostomy tube
  9. iPrevious invasive procedures include endoscopy and positioning of any device
  10. jImmunosuppressive therapy include corticosteroids, calcineurin inhibitors and monoclonal antibodies
  11. kOther coinfections include bacterial and/or fungal infections in sites other than blood
  12. lAppropriate antifungal therapy was considered when the appropriate drug with adequate dosage was started ≤ 72 h from the first blood culture performed